Drug intelligence / Profile preview

EDE1111

Development stage: Unknown
Lead developer: Eli Lilly

Overview

EDE1111 is a TSLP inhibitor in Phase 1 clinical development for the treatment of atopic dermatitis and other inflammatory skin diseases. Originally developed by Emergence Therapeutics, it was acquired by Eli Lilly to enhance its dermatology and immunology pipeline with a novel, upstream target for inflammatory disease control.

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on EDE1111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDE1111.

Explore the full profile